Telix Pharmaceuticals, the developer of cancer treatments and a favourite of local fund managers, will raise $US200 million ($300 million) and list on the Nasdaq later this year as it searches for deeper capital markets to fund its product development.

It is the second ASX-listed growth stock to flag intentions to list in New York, with Life360, the developer of family social media apps, to debut on the Nasdaq overnight.